Evidence map›Paper›PMID 33981529›Full record

ArticlePhysical therapy research2021

Risks of Muscle Atrophy in Patients with Malignant Lymphoma after Autologous Stem Cell Transplantation.

Keisuke Hirota, Hiroo Matsuse, Shunji Koya, Ryuki Hashida, Masafumi Bekki, Yoko Yanaga, Kiyoko Johzaki, Mami Tomino, Fumihiko Mouri, Satoshi Morishige and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physical therapy research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Semiquantitative 2-[Frontiers in medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keisuke HirotaDivision of Rehabilitation, Kurume University Hospital, Kurume, Japan.
Hiroo MatsuseDepartment of Orthopedics, Kurume University School of Medicine, Kurume, Japan.
Shunji KoyaDivision of Rehabilitation, Kurume University Hospital, Kurume, Japan.
Ryuki HashidaDepartment of Orthopedics, Kurume University School of Medicine, Kurume, Japan.
Masafumi BekkiDepartment of Orthopedics, Kurume University School of Medicine, Kurume, Japan.
Yoko YanagaDepartment of Nursing, Kurume University Hospital, Kurume, Japan.
Kiyoko JohzakiDepartment of Nursing, Kurume University Hospital, Kurume, Japan.
Mami TominoDepartment of Nursing, Kurume University Hospital, Kurume, Japan.
Fumihiko MouriDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Satoshi MorishigeDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Shuki OyaDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Yoshitaka YamasakiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Naoto ShibaDepartment of Orthopedics, Kurume University School of Medicine, Kurume, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMuscle atrophy is associated with autologous stem cell transplantation (ASCT)-related outcomes in patients with malignant lymphoma (ML). However, the impact of ASCT on muscle mass remains unclear in patients with ML. The aims of this study were to investigate changes in muscle mass and risk profiles for muscle atrophy after ASCT.

methodWe enrolled 40 patients with refractory ML (age 58 [20-74] years, female/male 16/24, body mass index (BMI) 21.1 kg/m STATISTICAL ANALYSIS USED: Independent factors associated with a severe decrease rate of change in PMI were evaluated by decision-tree analysis, respectively.

resultsPMI was significantly decreased after ASCT (4.61 vs. 4.55 cm

conclusionWe demonstrated that muscle mass decreased after ASCT in patients with ML. Patients who received MCEC and patients with low BMI were at risk for a decrease in muscle mass.

Indexed as

hematologic malignancieshematopoietic stem cell transplantationmuscle atrophysarcopeniaskeletal muscle index

Identifiers

PMID33981529
PMCPMC8111411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.